Mangoceuticals, Inc.

corporate_fare Company Profile

Mangoceuticals, Inc.

MGRX·NASDAQ·Industrial Applications And Services·CIK 0001938046

Mangoceuticals, Inc. develops, markets, and sells men's wellness products and services in the United States, primarily through a telemedicine platform. The company offers erectile dysfunction products under the Mango brand, hair loss products under the Grow brand, hormone balance and therapy products under the Mojo brand, and weight loss products under the Slim brand. It also provides oral testosterone undecanoate, marketed under the Prime brand, to treat low testosterone in men and for testosterone replacement therapy. Mangoceuticals facilitates customer access to a licensed pharmacy for online fulfillment and distribution of medications prescribed during telehealth consultations. The company markets and sells its products online via its website, www.MangoRX.com. Incorporated in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as a subsidiary of Cohen Enterprises, Inc.

Mangoceuticals, Inc. (NASDAQ:MGRX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors MGRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Mangoceuticals Q2 2026: Cash Drops to $229K, Going Concern Warning Reiterated, Nuclea Reverse Merger Details Emerge (2026-08-13)
Nuclea Energy to Acquire Moltex's Advanced Nuclear Tech Assets in Cash Deal (2026-08-13)
Merger partner Nuclea signs MOU with Utah to explore nuclear test reactor site, advancing microreactor demonstration (2026-08-05)
Mangoceuticals Secures 180-Day Nasdaq Reprieve, Eyes Reverse Split to Maintain Listing (2026-08-04)
Nuclea Energy Signs Definitive Reverse Merger with Mangoceuticals, Existing Shareholders to Hold Just 4% (2026-07-30)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

$456.02K

Net Income

-$20.64M

Diluted EPS

-$2.17

Op. Cash Flow

-$5.85M

Gross Profit

$250.39K

Operating Income

-$18.03M

Cash & Equivalents

$1.49M

Debt / Equity

0.00×

Net Margin

-45.27×

Shares Outstanding

15.89M sh

Source: 10-K · filed 2026-04-01 · accession 0001493152-26-014478

Dilution Risk

Low risk

Filing-implied dilution signals for MGRX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

Private Placement Completed · Deep Discount Pricing

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →

show_chartPrice Chart

Loading chart...

feed MGRX - Latest Insights

Filing Type

Date Range

MGRX

Aug 13, 2026, 5:27 PM EDT

Filing Type: 10-Q

Importance Score:

Mangoceuticals Q2 2026: Cash Drops to $229K, Going Concern Warning Reiterated, Nuclea Reverse Merger Details Emerge

Price at Filing: $0.625

Real-time Price: $0.4927

Change: -$0.1323 (-21%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Aug 13, 2026, 4:05 PM EDT

Source: GlobeNewswire

Importance Score:

Nuclea Energy to Acquire Moltex's Advanced Nuclear Tech Assets in Cash Deal

Price at Filing: $0.7485

Real-time Price: $0.4927

Change: -$0.2558 (-34%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Aug 05, 2026, 6:13 PM EDT

Filing Type: 425

Importance Score:

Merger partner Nuclea signs MOU with Utah to explore nuclear test reactor site, advancing microreactor demonstration

Price at Filing: $0.5363

Real-time Price: $0.4927

Change: -$0.0436 (-8%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Aug 04, 2026, 4:05 PM EDT

Filing Type: 8-K

Importance Score:

Mangoceuticals Secures 180-Day Nasdaq Reprieve, Eyes Reverse Split to Maintain Listing

Price at Filing: $0.441

Real-time Price: $0.4927

Change: +$0.0517 (+12%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Jul 30, 2026, 10:35 AM EDT

Source: TMX Newsfile

Importance Score:

Nuclea Energy Signs Definitive Reverse Merger with Mangoceuticals, Existing Shareholders to Hold Just 4%

Price at Filing: $0.3789

Real-time Price: $0.4927

Change: +$0.1138 (+30%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Jul 30, 2026, 7:01 AM EDT

Filing Type: 425

Importance Score:

Mangoceuticals to Merge with Nuclear Startup Nuclea Energy, Leaving Existing Shareholders with Just 4%

Price at Filing: $0.540

Real-time Price: $0.4927

Change: -$0.0473 (-9%)

Market Cap: $11.407M

Sentiment: Neutral

View Wiseek Article

MGRX

Jul 30, 2026, 7:00 AM EDT

Filing Type: 8-K

Importance Score:

Mangoceuticals Pivots from Men's Health to Advanced Nuclear via Reverse Merger with Nuclea Energy

Price at Filing: $0.540

Real-time Price: $0.4927

Change: -$0.0473 (-9%)

Market Cap: $11.407M

Sentiment: Neutral

View Wiseek Article

MGRX

Jul 02, 2026, 4:30 PM EDT

Filing Type: 8-K

Importance Score:

Mangoceuticals Raises $272K in Private Placement at Deep Discount

Price at Filing: $0.4555

Real-time Price: $0.4927

Change: +$0.0372 (+8%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

May 19, 2026, 4:30 PM EDT

Filing Type: 10-Q

Importance Score:

Mangoceuticals Reports Severe Cash Drain, Reiterates Going Concern, Faces Nasdaq Delisting, and Discloses Controversial CEO Subsidiary Agreement

Price at Filing: $0.4299

Real-time Price: $0.4927

Change: +$0.0628 (+15%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Apr 01, 2026, 6:31 AM EDT

Filing Type: 10-K

Importance Score:

MANGOCEUTICALS Faces Delisting Amid Soaring Losses, CEO Option Repricing, and Related Party Control of Core Assets

Price at Filing: $0.3622

Real-time Price: $0.4927

Change: +$0.1305 (+36%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Mar 17, 2026, 4:00 PM EDT

Filing Type: 8-K

Importance Score:

Mangoceuticals Reprices CEO Options, Files $73M Lawsuit Against Former Consultant

Price at Filing: $0.4005

Real-time Price: $0.4927

Change: +$0.0922 (+23%)

Market Cap: $11.407M

Sentiment: Neutral

View Wiseek Article

MGRX

Mar 17, 2026, 4:00 PM EDT

Source: GlobeNewswire

Importance Score:

Mangoceuticals Sues Former Tech Firm for $73M+ Over Failed Platform Delivery

Price at Filing: $0.4676

Real-time Price: $0.4927

Change: +$0.0251 (+5%)

Market Cap: $11.407M

Sentiment: Neutral

View Wiseek Article

MGRX

Mar 06, 2026, 4:02 PM EST

Source: Reuters

Importance Score:

Mangoceuticals Seeks Patent Expansion for MGX-0024 Antiviral to Cover Animal and Bird Infections

Price at Filing: $0.520

Real-time Price: $0.4927

Change: -$0.0273 (-5%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Feb 23, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Mangoceuticals' MGX-0024 Shows Strong Antiviral Efficacy in Poultry Trials, H5N1 Study

Price at Filing: $0.4855

Real-time Price: $0.4927

Change: +$0.0072 (+1%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Feb 19, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Mangoceuticals Reports 336% MoM Sales Growth for Injectable TRT Program, Cuts Customer Acquisition Costs by 54%

Price at Filing: $0.4966

Real-time Price: $0.4927

Change: -$0.0039 (-0.79%)

Market Cap: $11.407M

Sentiment: Positive

View Wiseek Article

MGRX

Feb 06, 2026, 4:30 PM EST

Filing Type: 8-K

Importance Score:

Mangoceuticals Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

Price at Filing: $0.382

Real-time Price: $0.4927

Change: +$0.1107 (+29%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Jan 23, 2026, 5:07 PM EST

Filing Type: S-1/A

Importance Score:

Amended S-1 Details Resale of 2.64M Shares by Selling Stockholders, Reinforcing Dilution Concerns Amidst Going Concern Warning

Price at Filing: $0.5383

Real-time Price: $0.4927

Change: -$0.0456 (-8%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

MGRX

Jan 13, 2026, 5:30 PM EST

Filing Type: S-1

Importance Score:

Resale Registration of 2.64M Shares by Selling Stockholders Amidst Going Concern Warning and Eli Lilly Lawsuit

Price at Filing: $0.7202

Real-time Price: $0.4927

Change: -$0.2275 (-32%)

Market Cap: $11.407M

Sentiment: Negative

View Wiseek Article

corporate_fare Company Profile